The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Phase 1Active Not RecruitingNCT05360615

Chulalongkorn University147 enrolled

Overview

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

147

Conditions

Empagliflozin in Post AKI Stage 2-3

Interventions

Empagliflozin 10 MGDRUG

SGLT2 inhibitors

PlaceboDRUG

Placebo

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * post AKI stage 2-3 * CrCl \> 20 Exclusion Criteria: * pregnancy * post kidney transplant * previous use of SGLT2 Inhibitors * history of ketoacidosis

Locations (1)

Central Chest Institute of Thailand

Nonthaburi, Mueang Nonthaburi District, Thailand

Outcomes

Primary Outcomes

MAKE365

Major adverse kidney events (number of participants with death, renal replacement therapy, New CKD, CKD progression)

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.